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Pyogenic liver abscess vs. Hepatocellular carcinoma, the challenge of diagnosis
without a biopsy.
Alberto Aguayo-Rico MD, Jennifer Jernigan MD.
University of New Mexico Health Sciences Center, Albuquerque, NM, USA

BACKGROUND

According to current guidelines, a mass found
incidentally or on screening in the setting of a
patient with known hepatitis B or cirrhosis of
other etiology is likely to be HCC [4]. Whenever
a liver lesion of more than 1 cm is present in
the right clinical setting, this should be either
evaluated by MRI or CT with contrast and if the
appearance is typical of HCC, then no further
investigations are required [4]. Unfortunately in
our case the initial CT was concerning but still
equivocal for HCC, in such cases the next
approach can be either pursuing another
imaging modality or trying to biopsy the lesion.
But after consultation with interventional
radiology it was deemed that the risk of the
percutaneous biopsy might be too elevated
since the patient had an elevated INR and
thrombocytopenic , therefore the second
imaging modality was chosen.

CASE DESCRIPTION

A liver mass in a cirrhotic liver should always raise the concern
for hepatocellular carcinoma (HCC), and expert guidelines state
that diagnosis can be made with imaging alone in some settings.
The causes of focal liver lesions are diverse, and may range from
benign lesions with an indolent clinical course to aggressive
malignant tumors. They are common findings as a result of the
increasing use of cross-sectional imaging techniques in patients
with nonspecific abdominal complaints. Clinical evaluation and
noninvasive radiologic imaging are critical for decision making in
the management of most patients with liver lesions [1].
Our case illustrates that care must be taken to consider other
etiologies before making that diagnosis.

A 57 year old man with alcoholic liver cirrhosis
came to the ED complaining of 1 month of severe,
intermittent abdominal pain with associated
subjective fever and chills. A CT abdomen on
admission reported 2 ill-defined hypodense liver
lesions concerning for HCC (left image). In the
setting of liver cirrhosis and a hepatic mass, work
up for HCC was initiated, including an AFP which
was later found to be normal. IR was consulted
for possible biopsy, however because the patient
had an elevated INR and thrombocytopenia it was
deferred and a triple phase MRI was instead
recommended to further evaluation. Infection was
initially lower on the differential due to lack of
fever and normal WBC. On hospital day 2 one of
the BCXs from admission revealed Streptococcus
viridians (later updated to Strep milleri). On
hospital day 3, fevers, tachycardia and
leukocytosis developed. An abscess was now
more likely. The patient was initially monitored
without antibiotics, but after the positive culture
and the episode of fever, he was started on
ceftriaxone and a second set of BCX were drawn
which later revealed the same organism. The MRI
showed two rim enhancing lesions in the right
hepatic lobe which in the setting of infectious
symptoms, were favored to represent abscesses
(right
image).
ID
was
consulted
and
recommended 6 weeks of IV ceftriaxone. A TEE
showed no evidence of endocarditis. A repeat CT
showed the masses to be decreased in size and
the patient was discharged with Clindamycin
300mg TID for an additional month. His last CT
continued to show evidence of improvement and
he was clinically improved as well, so
clindamycin was discontinued and he was
discharged from the Infectious Disease clinic.

DISCUSSION

A mass lesion seen in a patient with hepatitis B or C
infection, particularly when associated with features of
chronic liver disease, should raise the threshold for
suspicion of a malignancy, such as hepatocellular
carcinoma (HCC) [1]. Our patient came to the ED
complaining of vague symptoms of abdominal pain and
had concerning risk factors that makes a malignancy
higher in the differential diagnosis. The initial signs and
symptoms are typically indolent and advance lesions
may have mild to moderate upper abdominal pain,
weight loss, early satiety, or a palpable mass in the
upper
abdomen
[2].
Theoretically
the
anatomopathological assessment is the gold standard
for the diagnosis of any liver mass, however given the
invasiveness and procedural risks of the intervention is
not the initial tool for the diagnosis, specially with
accessible imaging modalities such as CT and MRI or
tumor markers such as Alpha-Fetoprotein (AFP). In a
setting such as our patient, a contrast CT scan of the
liver and/or magnetic resonance imaging (MRI) study is
often the initial diagnostic test. In patients with cirrhosis,
any dominant solid nodule that is not clearly a
hemangioma should be considered a HCC unless
proven otherwise [3].
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Another widely used tool is the serum marker
AFP, it is a glycoprotein that is normally
produced during gestation by the fetal liver and
yolk sac, the serum concentration of which is
often elevated in patients with HCC. However
the serum levels do not correlate well with
other clinical features of HCC, such as size,
stage, or prognosis. It could be elevated in
other conditions such as pregnancy, gonadal
origin neoplasms and other GI malignancies. It
is accepted that a level ˃500mcg/L in a high
risk patient is diagnostic of HCC [5]. However
over 40% of cases have normal levels [6]. Also
a variant of HCC called fibrolamellar carcinoma
have normal serum levels generally. Still its use
can be practical since its Sensitivity 41-65 %,
specificity 80-94 % positive likelihood ratio 3.1 6.8 and negative likelihood ratio 0.4 - 0.6 with a
cutoff of
>20 mcg/L [7]. Applying this
information into our case the level of AFP was
measured on admission but was reported as
normal, therefore still HCC could not be ruled
out since the sensitivity of the test is not high.

CONCLUSION

By following these recommendations, our patient who
had the common risk factors and worrisome
radiological findings of HCC was spared from an
invasive procedure and negative impact in his quality
of life by being diagnosed with cancer. Other factors
that contributed to pursue another diagnosis was
obtaining blood cultures on admission, which is
important to consider in the setting of a possible septic
picture. All these was achieved with out obtaining a
biopsy or culture from the mass, which even in the
setting of an abscess would be important to consider.
However the therapy was deemed appropriate since
subsequent CT scans showed regression of the
abscess.

WHY THIS CASE MATTERS?

1.

Reminds the clinician which risk factors are
concerning for a liver malignancy such as HCC but
still having in mind that other differential diagnosis
exist.

2.

Provides the primary care provider in the outpatient
setting the guidelines to work up a liver mass found
incidentally on abdominal imaging such as
ultrasound, CT or MRI.

3.

Demonstrates that HCC can be diagnosed without
the need of pathological confirmation, since most of
the patients have certain degree of coagulopathy
that can put them at periprocedural risk of bleeding
among others.
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